UROXATRAL- alfuzosin hydrochloride tablet, extended release

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Wirkstoff:

alfuzosin hydrochloride (UNII: 75046A1XTN) (alfuzosin - UNII:90347YTW5F)

Verfügbar ab:

Physicians Total Care, Inc.

INN (Internationale Bezeichnung):

alfuzosin hydrochloride

Zusammensetzung:

alfuzosin hydrochloride 10 mg

Verabreichungsweg:

ORAL

Verschreibungstyp:

PRESCRIPTION DRUG

Anwendungsgebiete:

UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. UROXATRAL is not indicated for use in the pediatric population. UROXATRAL is contraindicated for use: - in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. - with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)] . - in patients with known hypersensitivity, such as urticaria and angioedema, to alfuzosin hydrochloride or any component of UROXATRAL tablets [see Adverse Reactions (6.2)] Pregnancy Category B. UROXATRAL is not indicated for use in women, and there are no studies of alfuzosin in pregnant women Alfuzosin was not teratogenic, embryotoxic or

Produktbesonderheiten:

UROXATRAL is supplied as follows: UROXATRAL (alfuzosin HCl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10. Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light and moisture. Keep UROXATRAL out of reach of children.

Berechtigungsstatus:

New Drug Application

Fachinformation

UROXATRAL - ALFUZOSIN HYDROCHLORIDE TABLET, EXTENDED RELEASE
PHYSICIANS TOTAL CARE, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
UROXATRAL SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR UROXATRAL.
UROXATRAL (ALFUZOSIN HCL) EXTENDED-RELEASE TABLETS
INITIAL U.S. APPROVAL: 2003
RECENT MAJOR CHANGES
Indications and Usage (1.1)
12/2010
Warnings and Precautions, PDE5 inhibitors (5.4)
04/2010
Warnings and Precautions, Priapism (5.7)
12/2010
INDICATIONS AND USAGE
UROXATRAL is an alpha adrenergic antagonist, indicated for the
treatment of signs and symptoms of benign prostatic
hyperplasia. (1)
Important Limitations of Use:
UROXATRAL is not indicated for treatment of hypertension. (1.1)
UROXATRAL is not indicated for use in the pediatric population. (1.1,
8.4, 12.3)
DOSAGE AND ADMINISTRATION
10 mg once daily with food and with the same meal each day. (2)
Tablets should not be chewed or crushed (2, 12.3)
DOSAGE FORMS AND STRENGTHS
Extended-release tablet: 10 mg (3)
CONTRAINDICATIONS
Moderate or severe hepatic impairment (4, 8.7, 12.3)
Co-administration with potent CYP3A4 inhibitors (e.g. ketoconazole,
itraconazole, ritonavir) (4, 5.4, 7.1, 12.3)
Known hypersensitivity (e.g., urticaria or angioedema) to alfuzosin or
any of the ingredients (4, 6.2)
WARNINGS AND PRECAUTIONS
Postural hypotension/syncope: Care should be taken in patients with
symptomatic hypotension or who have had a
hypotensive response to other medications or are concomitantly treated
with antihypertensive medication or nitrates
(5.1)
Use with caution in patients with severe renal impairment (creatinine
clearance <30 mL/min) (5.2, 8.6, 12.3)
Use with caution in patients with mild hepatic impairment (5.3, 8.7,
12.3)
Should not be used in combination with other alpha adrenergic
antagonists (5.4, 7.2)
Prostate carcinoma should be ruled out prior to treatment (5.5)
Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery may
require modifications to the surgical tech